Anke Biotech announced that its wholly-owned subsidiary Soho Yiming's itivatide API was approved for marketing by the State Drug Administration. This indicates that the product is eligible to enter the domestic market, which helps to enrich the product pipeline, expand business areas, and enhance the company's core competitiveness. Etifibatide is used to treat patients with acute coronary syndrome by inhibiting platelet aggregation.

Anke Biotech announced that its wholly-owned subsidiary Soho Yiming's itivatide API was approved for marketing by the State Drug Administration. This indicates that the product is eligible to enter the domestic market, which helps to enrich the product pipeline, expand business areas, and enhance the company's core competitiveness. Etifibatide is used to treat patients with acute coronary syndrome by inhibiting platelet aggregation.